Absci Corporation · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-31$4.28 RISE2026-03-12$2.30 PEAK2026-05-29$6.75 210d | -46.3% 132d | Missed | Missed | — | — | +193.5% 78d | Missed |
DROP2025-10-15$5.00 RISE2025-11-13$2.64 PEAK2026-01-07$4.02 84d | -47.2% 29d | Missed | Missed | — | — | +52.3% 55d | Missed |
DROP2025-07-22$3.63 RISE2025-09-02$2.34 PEAK2025-10-15$5.00 85d | -35.5% 42d | Missed | Missed | — | — | +113.7% 43d | Missed |
DROP2025-03-05$3.36 RISE2025-07-15$2.57 PEAK2025-10-08$4.18 217d | -23.5% 132d | Missed | Missed | — | — | +62.6% 85d | Missed |
DROP2025-02-19$5.57 RISE2025-06-30$2.57 PEAK2025-07-22$3.63 153d | -53.9% 131d | Missed | Missed | — | — | +41.2% 22d | Missed |
DROP2025-02-14$5.82 RISE2025-04-03$2.24 PEAK2025-04-24$3.22 69d | -61.6% 48d | Missed | Missed | — | — | +44.1% 21d | Missed |
DROP2024-08-27$4.49 RISE2024-12-31$2.62 PEAK2025-02-14$5.82 171d | -41.6% 126d | Missed | Missed | — | — | +122.1% 45d | Missed |
DROP2024-08-27$4.49 RISE2024-11-21$2.55 PEAK2025-02-14$5.82 171d | -43.2% 86d | Missed | Missed | — | — | +128.2% 85d | Missed |
DROP2024-05-06$5.21 RISE2024-09-09$3.50 PEAK2024-09-20$4.32 137d | -32.8% 126d | Missed | Missed | — | — | +23.4% 11d | Missed |
DROP2024-04-09$6.59 RISE2024-06-20$2.92 PEAK2024-08-23$4.49 136d | -55.7% 72d | Missed | Missed | — | — | +53.8% 64d | Missed |
DROP2024-03-04$5.74 RISE2024-03-18$4.66 PEAK2024-04-09$6.59 36d | -18.8% 14d | Missed | Missed | — | — | +41.3% 22d | Missed |
DROP2023-07-21$2.41 RISE2023-10-26$1.15 PEAK2023-12-27$4.79 159d | -52.3% 97d | Missed | Missed | — | — | +316.5% 62d | Missed |
DROP2023-07-21$2.41 RISE2023-08-22$1.52 PEAK2023-09-01$1.87 42d | -36.9% 32d | Missed | Missed | — | — | +23.0% 10d | Missed |
DROP2023-02-24$2.24 RISE2023-07-06$1.42 PEAK2023-07-21$2.41 147d | -36.6% 132d | Missed | Missed | — | — | +69.7% 15d | Missed |
DROP2023-02-06$3.41 RISE2023-05-16$1.17 PEAK2023-07-21$2.41 165d | -65.7% 99d | Missed | Missed | — | — | +106.0% 66d | Missed |
1–15 / 24 1 / 2 | |||||||
Top analysts change outlook on top names. Check out analyst ratings page for all changes. RMIX, ABSI, and ORGO get coverage with targets.
BTIG analyst Kambiz Yazdi initiates coverage on Absci (NASDAQ:ABSI) with a Buy rating and announces Price Target of $9.
A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself.
Insiders who bought Absci Corporation ( NASDAQ:ABSI ) in the last 12 months may probably not pay attention to the...
AMD Reveals Marvell Stake, Sending Chip Stock Higher
AMD discloses a new position in Marvell Technology in its latest 13F filing, revealing a stake that has already delivered a sharp paper gain.
Tempus AI, Inc. leverages AI precision medicine, genomic diagnostics, & data licensing to scale growth; key metrics & guidance signal upside. Click for more on TEM.
Truist Securities analyst Srikripa Devarakonda maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $9 to $11.
Absci Corporation (ABSI) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsAlexander Khan - CVP of Finance & Head of Investor...
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. My name is Duncan, and I will be your conference operator for today. I would like to welcome you to Absci
ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Absci's Q1 revenue of $0.2M missed estimates by 86%, causing a 19% stock drop. Clinical progress on ABS-201 for hair loss offers hope, but market remains cautious.
Joining me today are Sean McClain, Absci Corporation's Founder and CEO; Zach Jonasson, Chief Financial Officer and Chief Business Officer; and Ronti Somerotne, Chief Medical Officer. Certain statements may also include projections regarding potential market opportunity.
Absci (NASDAQ:ABSI) executives on Wednesday outlined a “data-rich” 2026 anchored by multiple clinical updates for ABS-201, the company’s anti-prolactin receptor antibody being studied in androgenetic alopecia (AGA), and plans to expand a broader prolactin-focused pipeline with a newly disclosed prog
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 9.52 percent increase over losses of $(0.21) per share from the same
GENERATIVE AI DRUG CREATION Corporate Presentation May 2026 CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS...
Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President
This is not just a speculative AI rally. The pattern running through the strongest performers is more specific: the market is beginning to reward the physical stack behind AI. Read more here
VANCOUVER, Wash. and NEW YORK, May 04, 2026 -- Absci Corporation , a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABSI | +37.20% | +141.07% | +93.41% | +154.72% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +34.23% | +146.79% | +96.85% | +142.03% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 22.55M | $67.65M | 0.00% | Added+0.8% | 2026-03-31 |
| ARKK | disruptive | 13.73M | $41.18M | 0.32% | Added+9.4% | 2026-03-31 |
| StateStreet | passive | 7.32M | $21.97M | 0.00% | Added+22.3% | 2026-03-31 |
| TwoSigma | quant | 2.90M | $8.70M | 0.01% | Added+104.4% | 2026-03-31 |
| DEShaw | quant | 649.8K | $1.95M | 0.00% | New | 2026-03-31 |
| Wellington | fundamental | 366.8K | $1.10M | 0.00% | Trimmed-10.6% | 2026-03-31 |
| TRowePrice | fundamental | 117.6K | $353 | 0.00% | Trimmed-94.5% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-13 | Pangalos Menelas N | Director | P Open-market purchase | 37,453 | $5.36 | +$200.7K |
| 2026-03-16 | Busch Andreas | Chief Innovation Officer | P Open-market purchase | 100,000 | $2.29 | +$229.0K |
| 2026-03-05 | Pangalos Menelas N | Director | A Grant / award(deriv) | 22,800 | — | +$0 |
| 2026-03-05 | Pangalos Menelas N | Director | A Grant / award | 5,800 | — | +$0 |
| 2026-03-04 | Busch Andreas | Chief Innovation Officer | F Tax withholding | 1,257 | $2.80 | −$3.5K |
| 2026-03-04 | Jonasson Zachariah | CFO / CBO | A Grant / award(deriv) | 534,400 | — | +$0 |
| 2026-03-04 | Jonasson Zachariah | CFO / CBO | F Tax withholding | 10,848 | $2.80 | −$30.4K |
| 2026-03-04 | Jonasson Zachariah | CFO / CBO | A Grant / award | 135,400 | — | +$0 |
| 2026-03-04 | Bedrick Todd | SVP, CAO | A Grant / award(deriv) | 195,900 | — | +$0 |
| 2026-03-04 | Bedrick Todd | SVP, CAO | F Tax withholding | 5,282 | $2.80 | −$14.8K |
| 2026-03-04 | Bedrick Todd | SVP, CAO | A Grant / award | 49,600 | — | +$0 |
| 2026-03-04 | McClain Sean | Chief Executive Officer | A Grant / award(deriv) | 1,603,200 | — | +$0 |
| 2026-03-04 | McClain Sean | Chief Executive Officer | F Tax withholding | 25,316 | $2.80 | −$70.9K |
| 2026-03-04 | McClain Sean | Chief Executive Officer | A Grant / award | 406,200 | — | +$0 |
| 2026-03-04 | Walker Shelby J. | Chief Legal Officer | A Grant / award(deriv) | 356,300 | — | +$0 |
| 2026-03-04 | Walker Shelby J. | Chief Legal Officer | F Tax withholding | 9,825 | $2.80 | −$27.5K |
| 2026-03-04 | Walker Shelby J. | Chief Legal Officer | A Grant / award | 90,300 | — | +$0 |
| 2026-03-03 | Pangalos Menelas N | Director | P Open-market purchase | 75,095 | $2.74 | +$205.8K |
| 2026-03-03 | Jonasson Zachariah | CFO / CBO | F Tax withholding | 8,307 | $2.74 | −$22.8K |
| 2026-02-25 | McClain Sean | Chief Executive Officer | M Option exercise(deriv) | 396,399 | — | +$0 |
| 2026-02-25 | McClain Sean | Chief Executive Officer | F Tax withholding | 267,008 | $2.65 | −$707.6K |
| 2026-02-25 | McClain Sean | Chief Executive Officer | M Option exercise | 396,399 | $1.21 | +$479.6K |
| 2026-02-04 | Bedrick Todd | SVP, CAO | F Tax withholding | 3,659 | $2.99 | −$10.9K |
| 2026-02-04 | Jonasson Zachariah | CFO / CBO | S Open-market sale | 17,496 | $2.99 | −$52.3K |
| 2026-02-04 | McClain Sean | Chief Executive Officer | S Open-market sale | 26,761 | $2.99 | −$80.0K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-14upcoming | -0.20 | — | — |
| 2026-05-07 | -0.20 | -0.19 | +4.59% |
| 2026-03-24 | -0.17 | -0.23 | -32.54% |
| 2025-11-12 | -0.21 | -0.20 | +2.52% |
| 2025-08-12 | -0.21 | -0.24 | -15.07% |
| 2025-05-13 | -0.22 | -0.21 | +5.97% |
| 2025-03-18 | -0.22 | -0.25 | -11.73% |
| 2024-11-12 | -0.19 | -0.24 | -23.08% |
| 2024-08-14 | -0.20 | -0.22 | -11.11% |
| 2024-05-14 | -0.20 | -0.22 | -11.86% |
| 2024-03-21 | -0.22 | -0.25 | -12.61% |
| 2023-11-14 | -0.22 | -0.24 | -7.46% |
| 2023-08-14 | -0.24 | -0.22 | +6.74% |
| 2023-05-15 | -0.24 | -0.26 | -9.47% |
| 2023-03-30 | -0.25 | -0.21 | +15.32% |
| 2022-11-09 | -0.28 | -0.30 | -7.79% |